Skip to main content

Branded

  • GBI Research: Opioid market to surpass $17 billion by 2021
    LONDON — GBI Research published a report Thursday that noted the U.S. market for opioids will be growing in the coming years. According to the report, the opioid market will hit $17.7 billion by 2021, up from $11 billion in 2014, with a compound annual growth rate of 7%. 
     
    The report attributes the growth to a concurrent increase in chronic pain in the United States, stemming from an aging population and more incidences of such chronic diseases as diabetes, obesity, cancer, arthritis and cardiovascular disease. 

  • Flu incidence abating in Oregon, California according to latest Walgreens Flu Index report
    DEERFIELD, Ill. - The incidence of flu is beginning to abate across California and Oregon, according to the latest Walgreens Flu Index report. However, flu activity is still relatively high across Wyoming, Montana and Kentucky, according to the report. 
     
    The top 10 markets with flu activity for the week of March 27 were: 
     
    1. El Paso, Texas (Las Cruces, N.M.);
    2. Harlingen – Weslaco – Brownsville – McAllen, Texas;
    3. Louisville, Ky.;

  • FTC sues Endo, others on pay-for-delay allegations
    WASHINGTON — The Federal Trade Commission announced Thursday that it had filed a complaint against Endo Pharmaceuticals and several other drug companies alleging that it violated antitrust laws by paying settlements to drug makers to delay the introduction of generic versions of Opana ER and Lidoderm. 
     
    The FTC said this is the first case that’s challenged an agreement to not market an authorized generic of a particular drug, which it calls no-AG commitments. 
     

  • Alliance for Aging Research posts 'pocket film' on safe medication disposal

  • IMS Health report highlights potential of biosimilars
    PARSIPPANY, N.J. — IMS Health on Tuesday published a new report about the potential for biosimilars in the United States and the European Union. The report, “Delivering on the Potential of Biosimilar Medicines:  The Role of Functioning Competitive Markets,” focuses on the savings that biosimilars can deliver for patients and payers, as well as the access to advanced treatments they offer payers. 
     

  • Report: Russian pharmacies sees spike in meldonium sales

  • Special DSN report examines pharmacy’s ‘impact’

    Drug Store News in March published the fifth edition of RxImpact, a special supplement to DSN, produced in support of the National Association of Chain Drug Stores’ RxImpact Day on Capitol Hill. The special Rx-Impact report — inserted in headquarter copies of this issue of DSN and delivered to all current members of the U.S.

  • Novo Nordisk breaks ground on $1.8 billion N.C. production facility
    CLAYTON, N.C. — Novo Nordisk announced Monday that it had broken ground on its new facility where it will produce diabetes medicine. The $1.8 billion facility’s ground breaking event was attended by the company’s president and CEO Lars Rebien Sørensen, as well as N.C. Gov. Pat McCrory and more than 100 employees, policy makers and community members. 
     
X
This ad will auto-close in 10 seconds